Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
19 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 33
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
Europe
🇬🇧 United KingdomGB-S01 · MHRA / GOV.UK · UK-wide licensing for human medicines; Windsor Framework medicines explainerOfficialUK-wide licence, Category 1/2, UK Only, NI transitioneffective 2025-01-01Latest observed: 2025-03-12 / current🇬🇧 United KingdomGB-S01 · MHRA / GOV.UK · UK-wide licensing for human medicines; Windsor Framework medicines explainerOfficialUK-wide licence, Category 1/2, UK Only, NI transitioneffective 2025-01-01Latest observed: 2025-03-12 / current🇬🇧 United KingdomGB-S02 · MHRA / GOV.UK · National assessment procedure; International Recognition Procedure supplementary information; MHRA performance dataOfficialnational/IRP routes, timelines, performance, variationsnational published 2025-04-03Latest observed: 2026-04-09 / 2026-07-14 / June 2026 data🇬🇧 United KingdomGB-S02 · MHRA / GOV.UK · National assessment procedure; International Recognition Procedure supplementary information; MHRA performance dataOfficialnational/IRP routes, timelines, performance, variationsnational published 2025-04-03Latest observed: 2026-04-09 / 2026-07-14 / June 2026 data🇬🇧 United KingdomGB-S02 · MHRA / GOV.UK · National assessment procedure; International Recognition Procedure supplementary information; MHRA performance dataOfficialnational/IRP routes, timelines, performance, variationsnational published 2025-04-03Latest observed: 2026-04-09 / 2026-07-14 / June 2026 data🇬🇧 United KingdomGB-S03 · MHRA and UK access partners · Innovative Licensing and Access PathwayOfficialInnovation Passport, TDP, cross-system coordination2025-01-30Latest observed: 2026-05-19🇬🇧 United KingdomGB-S04 · MHRA / GOV.UK · Early Access to Medicines Scheme overviewOfficialPIM, scientific opinion, duration, pre-licence boundarycurrent scheme under HMR 167CLatest observed: 2026-03-02🇬🇧 United KingdomGB-S05 · DHSC / GOV.UK · Introducing new medicines in the NHS in the UK — pathwayOfficialend-to-end, list price, PAS, four nationscurrent pathwayLatest observed: checked live🇬🇧 United KingdomGB-S06 · DHSC / NHS England / ABPI · 2024 VPAG and 2026 payment percentageOfficialvoluntary portfolio scheme, 14.5%, 15% capscheme 2024-01-01 to 2028-12-31Latest observed: scheme updated 2026-06-02; rate published 2025-12-10🇬🇧 United KingdomGB-S06 · DHSC / NHS England / ABPI · 2024 VPAG and 2026 payment percentageOfficialvoluntary portfolio scheme, 14.5%, 15% capscheme 2024-01-01 to 2028-12-31Latest observed: scheme updated 2026-06-02; rate published 2025-12-10🇬🇧 United KingdomGB-S07 · DHSC / GOV.UK · Proposed 2026 changes to statutory scheme — outcomeOfficialstatutory 16.5% and VPAG equivalence rationale2026 changesLatest observed: 2026-06-10🇬🇧 United KingdomGB-S08 · NICE · NICE TA and HST guidance: PMG36 and interim EQ-5D-5L methods statement PMG51Officialscope, evidence, EQ-5D-5L UK value set and transition, £25k–£35k, severity, HST, recommendations, managed accessPMG36 published 2022-01-31; PMG51 published/effective prospectively 2026-08-27Latest observed: PMG51 2026-08-27🇬🇧 United KingdomGB-S08 · NICE · NICE TA and HST guidance: PMG36 and interim EQ-5D-5L methods statement PMG51Officialscope, evidence, EQ-5D-5L UK value set and transition, £25k–£35k, severity, HST, recommendations, managed accessPMG36 published 2022-01-31; PMG51 published/effective prospectively 2026-08-27Latest observed: PMG51 2026-08-27🇬🇧 United KingdomGB-S08 · NICE · NICE TA and HST guidance: PMG36 and interim EQ-5D-5L methods statement PMG51Officialscope, evidence, EQ-5D-5L UK value set and transition, £25k–£35k, severity, HST, recommendations, managed accessPMG36 published 2022-01-31; PMG51 published/effective prospectively 2026-08-27Latest observed: PMG51 2026-08-27🇬🇧 United KingdomGB-S09 · NICE · PMG36 developing guidance and update informationOfficial£40m BIT, PAS/CAA, loss-of-exclusivity rapid updatecurrent manualLatest observed: BIT changed 2025-06; manual updated 2026-03-31🇬🇧 United KingdomGB-S09 · NICE · PMG36 developing guidance and update informationOfficial£40m BIT, PAS/CAA, loss-of-exclusivity rapid updatecurrent manualLatest observed: BIT changed 2025-06; manual updated 2026-03-31🇬🇧 United KingdomGB-S10 · NICE · About / What is technology appraisal guidanceOfficiallegal funding duty and usual 3-month availabilitycurrentLatest observed: checked live🇬🇧 United KingdomGB-S10 · NICE · About / What is technology appraisal guidanceOfficiallegal funding duty and usual 3-month availabilitycurrentLatest observed: checked live🇬🇧 United KingdomGB-S11 · NICE · Managed accessOfficialDCA + commercial agreement, up to 5 years, CDF/IMFcurrentLatest observed: checked 2026-08-01🇬🇧 United KingdomGB-S12 · NHS England · NHS commercial framework for new medicinesOfficialPAS, CAA, commercial principles, combination therapy; old threshold conflict flaggedframework updated Jan 2025Latest observed: Jan 2025🇬🇧 United KingdomGB-S13 · NHS England · Provider reimbursement in managed access funds — SOPOfficialBlueteq, CAP price, CDF/IMF provider reimbursementcurrent SOPLatest observed: checked live🇬🇧 United KingdomGB-S14 · NHS England · Medicines procurement and supply chain; 2026/27 NHS Payment Scheme; specialised commissioning/IFROfficialhospital frameworks, high-cost drugs, commissioning, IFRcurrentLatest observed: 2026🇬🇧 United KingdomGB-S14 · NHS England · Medicines procurement and supply chain; 2026/27 NHS Payment Scheme; specialised commissioning/IFROfficialhospital frameworks, high-cost drugs, commissioning, IFRcurrentLatest observed: 2026🇬🇧 United KingdomGB-S14 · NHS England · Medicines procurement and supply chain; 2026/27 NHS Payment Scheme; specialised commissioning/IFROfficialhospital frameworks, high-cost drugs, commissioning, IFRcurrentLatest observed: 2026🇬🇧 United KingdomGB-S15 · SMC · Making a submissionOfficialSMC remit, pre-MA submission, 18/22–26 weeks, PASAGcurrent processLatest observed: checked live🇬🇧 United KingdomGB-S16 · SMC / Scottish Government · PACE; ultra-orphan; outwith-remit change; formulary 90-day interpretationOfficialPACE, ultra-orphan, generic/biosimilar, Board decision vs implementationcurrent / 2024 changeLatest observed: checked 2026-08-01🇬🇧 United KingdomGB-S16 · SMC / Scottish Government · PACE; ultra-orphan; outwith-remit change; formulary 90-day interpretationOfficialPACE, ultra-orphan, generic/biosimilar, Board decision vs implementationcurrent / 2024 changeLatest observed: checked 2026-08-01🇬🇧 United KingdomGB-S16 · SMC / Scottish Government · PACE; ultra-orphan; outwith-remit change; formulary 90-day interpretationOfficialPACE, ultra-orphan, generic/biosimilar, Board decision vs implementationcurrent / 2024 changeLatest observed: checked 2026-08-01🇬🇧 United KingdomGB-S16 · SMC / Scottish Government · PACE; ultra-orphan; outwith-remit change; formulary 90-day interpretationOfficialPACE, ultra-orphan, generic/biosimilar, Board decision vs implementationcurrent / 2024 changeLatest observed: checked 2026-08-01🇬🇧 United KingdomGB-S17 · AWTTC / NHS Wales · Updated AWMSG process; how medicines are approved for use in NHS WalesOfficialNICE/AWMSG boundary, Scrutiny Panel, 60 days, IPFR/local formularynew process 2025-01-01Latest observed: current page checked 2026-08-01🇬🇧 United KingdomGB-S17 · AWTTC / NHS Wales · Updated AWMSG process; how medicines are approved for use in NHS WalesOfficialNICE/AWMSG boundary, Scrutiny Panel, 60 days, IPFR/local formularynew process 2025-01-01Latest observed: current page checked 2026-08-01🇬🇧 United KingdomGB-S18 · NI Department of Health · Circular HSC (SQSD) 12/22Officialendorsement, 4 weeks, 15 weeks, Trust 3+6 months, PASeffective 2022-04-01Latest observed: current circular🇬🇧 United KingdomGB-S19 · NI Department of Health · Review of Access Pathways for Medicines Within HSC NIOfficialcurrent-system review, £875m context, reform-not-yet-implemented boundary2025-10-02Latest observed: 2025-10-02For education only — not regulatory, pricing or legal advice.